Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
EyePoint, Inc. develops and commercializes therapeutics for serious retinal diseases as a clinical-stage biopharmaceutical company. Its lead product candidate, DURAVYU (vorolanib intravitreal insert), is an investigational sustained-delivery treatment that uses bioerodible Durasert E technology and is being studied for wet age-related macular degeneration and diabetic macular edema.
Recurring EyePoint news covers clinical program updates, financial results, FDA naming and product-status disclosures, manufacturing and commercial-readiness topics, investor presentations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Company updates also address cash resources, corporate development activity, and disclosures tied to its Nasdaq-listed common stock.
EyePoint (Nasdaq:EYPT) reported second quarter 2026 net revenue of $0.5 million, down from $5.3 million a year earlier, with operating expenses of $97.9 million and a net loss of $94.5 million ($1.09 per share). Cash, cash equivalents and marketable securities totaled $180 million as of June 30, 2026, which the company expects will fund operations into the fourth quarter of 2027.
EyePoint highlighted progress for lead candidate DURAVYU (vorolanib intravitreal insert). Topline data from the pivotal Phase 3 LUGANO wet AMD trial are expected in August 2026, with LUCIA data anticipated in Q4 2026. Pivotal Phase 3 DME trials COMO and CAPRI have fully enrolled over 480 patients, with topline data expected in Q4 2027. A May 2026 DSMC review recommended LUGANO and LUCIA continue without protocol changes, with masked safety data consistent with prior favorable experience. The company is scaling its commercial manufacturing facility and appointed Tarek S. Hassan, M.D., as Chief Strategic Science Officer in July 2026.
EyePoint (Nasdaq:EYPT) announced completion of enrollment in COMO and CAPRI, its two global pivotal Phase 3 trials of DURAVYU™ (vorolanib intravitreal insert) for diabetic macular edema (DME). More than 480 patients were enrolled across both studies in only five months, ahead of schedule. Topline 56-week data are anticipated in 4Q 2027.
COMO and CAPRI are randomized, double-masked, on-label 2mg aflibercept-controlled non-inferiority trials. Patients receive either DURAVYU 2.7mg dosed every six months or aflibercept. The primary endpoint is non-inferior change from baseline in best corrected visual acuity at weeks 52 and 56, with secondary endpoints including safety, treatment burden, supplemental injection need, and OCT anatomy.
According to EyePoint, an independent DSMC reviewed masked safety data in May 2026 and recommended both DURAVYU Phase 3 programs continue as planned without protocol changes. DURAVYU has been studied in over 190 patients across four completed trials, showing a favorable safety and tolerability profile with no DURAVYU-related safety concerns, and Phase 2 VERONA data informed the Phase 3 design.
EyePoint (Nasdaq:EYPT) granted non-statutory stock options as NASDAQ Listing Rule 5635(c)(4) inducement awards to two new employees on July 15, 2026. The options cover up to 63,500 common shares at an exercise price of $13.85, have a ten-year term, and vest over four years, subject to continued service.
EyePoint (Nasdaq:EYPT) appointed retina specialist Tarek S. Hassan, M.D. as Senior Vice President, Chief Strategic Science Officer, effective July 13, 2026. He will report to President and CEO Jay S. Duker, M.D., and join the executive leadership team.
Dr. Hassan will guide clinical development, potential commercialization, and pipeline strategy, including EyePoint’s lead program DURAVYU™ (vorolanib intravitreal insert), which is in Phase 3 trials for wet age-related macular degeneration. In connection with his hiring, EyePoint granted Dr. Hassan stock options for 100,000 shares, with an exercise price equal to EyePoint’s July 13, 2026 closing price and vesting over four years.
EyePoint (Nasdaq:EYPT) granted non-statutory stock options as inducement awards to three new employees under NASDAQ Listing Rule 5635(c)(4). The awards cover up to 39,700 shares of common stock, granted June 15, 2026, with a ten-year term and exercise price of 12.08 per share.
Options vest over four years, with 25% after one year and the remainder in equal monthly installments over three years, subject to continued employment.
EyePoint (Nasdaq:EYPT) announced management participation in three upcoming investor conferences focused on ophthalmology and healthcare.
Fireside chats are scheduled for May 26, June 3, and June 9, 2026, and will be available via live webcast and archived replay on the company's investor relations website.
EyePoint (Nasdaq:EYPT) granted non-statutory stock options as inducement awards to eight new employees under NASDAQ Listing Rule 5635(c)(4), outside its 2023 Long-Term Incentive Plan.
The options cover up to 158,100 shares at an exercise price of $12.35, with a ten-year term and four-year vesting.
EyePoint (Nasdaq:EYPT) reported a third consecutive positive recommendation from the independent DSMC for its pivotal Phase 3 DURAVYU wet AMD trials, LUGANO and LUCIA, allowing both to continue without protocol changes.
Enrollment is complete with over 900 patients, topline LUGANO data targeted for mid-2026, and LUCIA to follow. All active treatment-arm patients reached Week 32 for a second dose, with over 35% receiving a third dose at Week 56. Masked safety data remain favorable and consistent with four earlier trials.
EyePoint (Nasdaq: EYPT) reported Q1 2026 results and corporate updates on May 6, 2026. Key clinical milestones: Phase 3 wet AMD trials LUGANO and LUCIA remain on track with topline data expected beginning mid-2026; Phase 3 DME COMO and CAPRI are >33% enrolled with full enrollment expected Q3 2026.
Financials: Q1 revenue $0.7M, operating expenses $87.9M, net loss $84.8M (−$0.99/share), and $223M cash and investments as of March 31, 2026, supporting runway into Q4 2027.
EyePoint (Nasdaq: EYPT) will report first quarter 2026 financial results on May 6, 2026 and will host a conference call and live audio webcast at 8:30 a.m. ET to discuss results and recent corporate developments.
Registration is required for the live call; a webcast replay will be available on the company website.